Enfusion shares are trading lower after the company reported worse-than-expected Q2 financial results and issued FY23 revenue guidance below estimates.
Portfolio Pulse from Benzinga Newsdesk
Enfusion reported worse-than-expected Q2 financial results and issued FY23 revenue guidance below estimates, causing its shares to trade lower.
August 08, 2023 | 4:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Enfusion's shares are trading lower due to worse-than-expected Q2 results and lower FY23 revenue guidance.
Enfusion's worse-than-expected Q2 results and lower FY23 revenue guidance are negative indicators for the company's financial health, which has led to a decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100